Acne is the most common dermatological disorder worldwide, occurring when sebaceous glands are clogged with dead skin cells and oil from the skin. Within these sebaceous glands, Cutibacterium acnes is the most prevalent and abundant species, representing approximately 90% of the local skin microbiome. Although being part of the healthy skin microbiome, C. acnes is directly involved in the disease pathogenesis of acne through several mechanisms:
- stimulation of sebum production,
- promotion of comedones formation and
- triggering and aggravation of inflammation.*
*Fitz-Gibbon et al. (2013); McDowell et. al.(2012); etc.
Artilysin® is the solution
Lysando’s scientists managed to create the world´s first lysin targeting C. acnes and therefore have set a milestone.
Based on these molecules, innovative products will be developed to selectively target C. acnes without creating resistant bacteria and with a high safety profile. The main focus of the development will be to balance the skin microbiome by reducing only the overgrown pathogen C. acnes whilst leaving the commensal microorganisms intact. This secures a healthy skin microbiome.
Artilysin®s are predestined to reshape the acne market.